profit from every $100 of sales.
$0$100
Arcturus Therapeutics Holdings
$9.49-8.31% today
+8.8% in 1 year
1-year low $5.531-year high $16.93
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Arcturus Therapeutics Holdings sold, what it kept, and what it did with the cash.
Sales went from $206 million in 2022 to $67.2 million in 2025, with -$65.8 million of profit last year.
SalesProfit
Arcturus Therapeutics Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Arcturus Therapeutics Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Arcturus Therapeutics Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 206 | 158 | 138 | 67 | |
| – | – | – | – | |
| 12 | -78 | -96 | -76 | |
| 14 | -24 | -77 | -63 | |
| 9 | -30 | -81 | -66 | |
| 0.35 | -1.00 | -3.00 | -2.40 | |
| – | – | – | – | |
| 5.9% | -49.6% | -69.1% | -113.4% | |
| 4.5% | -18.8% | -58.5% | -97.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 450 | 429 | 344 | 271 |
| Cash | 392 | 292 | 237 | 231 |
| Total debt | 95 | 30 | 29 | 25 |
| Total liabilities | 180 | 151 | 103 | 57 |
| 270 | 279 | 241 | 214 | |
| 27 | 27 | 27 | 27 | |
| 2.6% | -6.9% | -23.7% | -21.7% | |
| 3.5% | -10.7% | -33.6% | -30.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 32 | -18 | -60 | -74 | |
| 8 | 3 | 1 | 0 | |
| 24 | -21 | -60 | -75 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 31 | 35 | 38 | 25 |
Valuation
- –
- –
- –
- 1.0×
- 4.1×
- –
- –
- -27.2%
- -24.1%
- 0.0%
Profitability
- 91.2%
- -113.4%
- -97.9%
- -160.5%
- -42.3%
- -26.6%
- -36.6%
- -32.1%
- -42.3%
- 216.6%
Growth
- −31.1%
- –
- −23.0%
- –
- +1.0%
Financial health
- -3.3×
- 0.10
- 8.0%
- –
- 6.31
- 6.31
- 0.18
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 11%of 948
Bottom 3%of 871
Bottom 3%of 868
Bottom 2%of 985
What analysts expect
- Average price target
- $22.50
- Range
- $20.00 – $25.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.95 | -1.01 | +6.0% |
| Mar 3, 2026 | -1.03 | -0.92 | −12.0% |
| Nov 10, 2025 | -0.49 | -0.80 | +38.7% |
| Aug 11, 2025 | -0.34 | -1.11 | +69.4% |
| May 12, 2025 | -0.52 | -1.58 | +67.1% |
| Mar 6, 2025 | -1.11 | -0.33 | −236.4% |
| Nov 7, 2024 | -0.26 | -0.70 | +62.9% |
| Aug 5, 2024 | -0.64 | -1.85 | +65.4% |
News
Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiencySeeking Alpha · Sep 23, 2026The newest story we have is from Sep 23, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
68Pass
Philip Fisher
49No pass
Peter Lynch
30No pass
Joel Greenblatt
2No pass
Charlie Munger
45No pass
Terry Smith
46No pass
Questions about Arcturus Therapeutics Holdings
Is Arcturus Therapeutics Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Arcturus Therapeutics Holdings AI analysis
What does Arcturus Therapeutics Holdings do?
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. It is in Biotechnology.
Does Arcturus Therapeutics Holdings pay a dividend?
No. Arcturus Therapeutics Holdings does not pay a dividend at the moment.
Is Arcturus Therapeutics Holdings stock halal?
No. Arcturus Therapeutics Holdings does not pass our halal screen: its cash and confirmed interest-bearing investments are 84% of its market value, at or above the 33% limit. How we check
How has Arcturus Therapeutics Holdings stock done over the past year?
Up 8.8% over the past twelve months, to $9.49. It traded between $5.53 and $16.93 and is 43.9% below its high.
Who are Arcturus Therapeutics Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Arcturus Therapeutics Holdings's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.